SEC Form 4 · accession 0001178913-18-001826
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley Hirsch
Director
Period of report
May 13, 2018
Accepted (ET)
May 31, 2018 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 13, 2018 | X | 6,224 | $5.04 | A | 12,672 | D | |
| Ordinary Shares | May 13, 2018 | S | 6,164 | $5.089 | D | 6,508 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy) | $5.04 | May 13, 2018 | X | 6,224 | D | May 14, 2013 | May 13, 2018 | Ordinary Shares | 6,224 | 0 | D |
Explanation of responses
- F1On May 13, 2018, warrants held by Mr. Hirsch for the purchase of up to 6,224 ordinary shares of the Issuer for $5.04 per share were automatically exercised on a net-issuance (cashless) basis upon their expiration, in accordance with their terms. This cashless exercise resulted in the Issuer withholding 6,164 of the warrant shares to pay the exercise price and issuing to Mr. Hirsch the remaining 60 shares.